Phaseline

Companies › Ausper Biopharma

Ausper Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 9 registered trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AHB-137
Immunomodulator for hepatitis B
–Phase 3Chronic Hepatitis BDec 2026
AHB-171 Injection–Phase 2Hepatitis B, Chronic (CHB); Chronic Hepatitis B InfectionDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07137910AHB-137Phase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT06829329AHB-137Phase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT07246889AHB-137Phase 3Chronic Hepatitis BInfectious diseaseDec 2026
NCT07635186AHB-137Phase 2Chronic Hepatitis BInfectious diseaseJun 2027
NCT07069569AHB-137Phase 2Chronic Hepatitis BInfectious diseaseJul 2027
NCT06993480AHB-137Phase 2Chronic Hepatitis BInfectious diseaseJul 2027
NCT07511218AHB-171 InjectionPhase 1Chronic Hepatitis B InfectionInfectious diseaseDec 2027
NCT07600788AHB-137Phase 1Chronic Hepatitis BInfectious diseaseMay 2028
NCT07630727AHB-171 InjectionPhase 2Hepatitis B, Chronic (CHB)Infectious diseaseMar 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Fujian Akeylink Biotechnology Laboratorio Farmaceutico SIT srl Amplexd Therapeutics Sano Chemicals Hyundai Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.